FENNEC PHARMACEUTICALS INC. (OTCMKTS:FENCF) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders. |
On June 27, 2017, Fennec Pharmaceuticals Inc. (the Company) held
an annual and special meeting of shareholders (the Meeting). The
shareholders approved all proposals considered at the Meeting and
approved all nominees of the Company for director, as follows:
1. The following five (5) nominees were elected to serve as
directors, each to serve until the next annual meeting of
shareholders of the Company or until their respective successor
shall have been duly elected or duly approved:
| Name of Nominee | Votes For | Votes Withheld | Broker Non-Votes |
| Dr. Khalid Islam | 9,243,659 | 2,562 | 1,326,909 |
| Adrian Haigh | 9,243,660 | 2,561 | 1,326,909 |
| Chris A. Rallis | 9,243,017 | 3,204 | 1,326,909 |
| Marco Brughera | 9,243,813 | 2,408 | 1,326,909 |
| Rostislav Raykov | 9,243,761 | 2,460 | 1,326,909 |
2. The resolution to appoint Haskell White LLP as independent
public accounting firm of the Company and to authorize the Board
of Directors to fix their remuneration was approved based on the
following vote:
| Votes For | 10,291,097 |
| Votes Withheld | 282,033 |
| Abstentions | |
| Broker Non-Votes |
3. The ordinary resolution to approve the Shareholder Rights Plan
Agreement was approved based on the following vote:
| Votes For | 9,244,726 |
| Votes Against | 1,495 |
| Abstentions | |
| Broker Non-Votes | 1,326,909 |
4. The resolution to vote on the advisory vote on executive
compensation was approved based on the following vote:
| Votes For | 9,242,927 |
| Votes Against | 3,294 |
| Abstentions | |
| Broker Non-Votes | 1,326,909 |
About FENNEC PHARMACEUTICALS INC. (OTCMKTS:FENCF)
Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company’s lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children’s Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.